Lilly’s Late-Stage CNS Pipeline Bare Following Edivoxetine Failure
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Depression candidate edivoxetine fails in three Phase III studies, marking a third recent blow to Lilly’s neuroscience pipeline efforts.